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Cancer immunotherapy focuses on the development of agents
that can activate the immune system to recognize and kill
tumour cells. It encompasses different strategies, the first of
which is the activation of innate and adaptive immune effector
mechanisms, such as vaccination with tumour antigens, treat-
ment with cytokines (for example, interleukin 2 or interferon
α) and enhancement of antigen presentation. Another impor-
tant strategy involves neutralizing the inhibitory and suppres-
sive mechanisms and includes the use of antibodies to deplete
the regulatory T cells and the use of antibodies against
immune-checkpoint molecules, for example cytotoxic T
lymphocyte-associated protein 4 (CTLA-4) and programmed
cell death (PD1) [1].
Monoclonal antibodies (mAbs) that block the immunoreg-
ulatory damping mechanisms of the host response to tumour-
associated antigens have recently become a practical reality
with the first approval by the US Food and Drug
Administration of ipilimumab in patients with unresectable
or metastatic melanoma. Ipilimumab is a fully human mono-
clonal immunoglobulin specific for CTLA-4, a molecule that
downregulates T-cell activation via a homeostatic feedback
loop. Under normal physiological conditions, this mechanism
prevents autoimmunity and allows the body to establish tol-
erance to self-antigens. Anti-CTLA-4 mAbs block CTLA-4
signalling preventing downregulation of the immune response
and increasing the proliferation of Tcells and the interaction of
T cells and cancer cells [2]. Ipilimumab has been extensively
tested in patients with melanoma. It was found to be the first
compound to improve overall survival in a randomized, phase
III trial comparing ipilimumab with or without the gp100
peptide vaccine versus gp100 alone in patients with previous-
ly treated, unresectable stage III or IV melanoma. Median
overall survival in the combination ipilimumab and vaccine
arm was similar to that in the ipilimumab-alone arm, but
significantly higher than in the gp100 peptide vaccine-alone
arm [3]. Another randomized phase III study demonstrated an
increase in overall survival in patients with previously untreat-
ed stage IV melanoma receiving dacarbazine in combination
with ipilimumab compared to dacarbazine alone [4].
Consistent with the mechanism of action of ipilimumab,
that does not rely on the direct killing of tumour cells, the
changes in tumour burden observed in clinical trials have
often been very different from those observed using chemo-
therapeutic agents. Four distinct patterns of response have
been described: (1) response in baseline target lesions, that is
a “chemotherapy-like” response; (2) a slow, steady decline in
tumour burden; (3) response after an increase in tumour
burden, that is after progressive disease (PD) by standard
response criteria; and (4) response in target and new lesions
accompanied by the appearance of other new lesions. All
these patterns are associated with favourable survival, al-
though the last two may be misinterpreted as PD by standard
methods [5].
Antibodies that target CTLA-4 have also been associated
with several novel adverse effects that have been described as
immune-related adverse events (irAEs). They are found in
more than 70 % of patients and are typically responsive to
interruption or discontinuation of CTLA-4 blockade in com-
bination with immunosuppressive drugs such as corticoste-
roids [6]. Symptomatic irAEs have been described mainly in
four organ systems: gastrointestinal tract, liver, skin and en-
docrine system. Clinically silent manifestations, in particular
benign lymphadenopathy (sarcoid-like syndrome) and
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inflammatory changes in soft tissues (myositis, fasciitis), have
also been reported and may be detected only during follow-up
whenCT,MRI or PET/CTare performed [6–11]. The different
patterns of response and the appearance of irAEs are poten-
tially consistent with the mechanism of action of CTLA-4
blockade, given the time it takes to generate an antitumour
immune response and interpatient variability in immune sys-
tem function. Therefore the assessment of response can be
difficult, if not misleading, by standard methods such as the
World Health Organization (WHO) criteria or Response
Evaluation Criteria in Solid Tumors (RECIST) [12, 13], that
were developed primarily to define the effect of cytotoxic
drugs. The effectiveness of immunotherapy may also be
misinterpreted using the PET Response Criteria in Solid
Tumors (PERCIST) [14], owing to the nonspecific mecha-
nism of uptake of the routinely used 18F-FDG.
In order to avoid these misinterpretations we first need
specific criteria for evaluation of response to the different
types of immunotherapy now available, as have been devel-
oped in radiology. Indeed several new response criteria are
being proposed and even applied in oncology trials in selected
cancer patients receiving molecular targeted agents, such as
the response criteria of Choi et al. for metastatic GIST treated
with imatinib [15, 16] and the immune-related response
criteria (irRC) for metastatic melanoma treated with
ipilimumab [17]. Moreover, in patients treated with anti-
CTLA-4 mAbs, a close collaboration with the clinician is
required to define the optimal timing of the PET/CT scan,
given the different times of onset and resolution of irAEs [18].
In this way considering the appearance of new PET-positive
lesions as PD, that can lead to the early discontinuation of an
effective therapy, can be avoided. We can also suggest the use
of FDG PET in the early evaluation of response to treatment
with ipilimumab. Indeed, a flare reaction (with an increase in
the extent and uptake of known lesions and the appearance of
irAE) may be predictive of response to therapy [19, 20].
Prospective studies are needed to resolve this point so that
unnecessary treatments can be avoided, the correct timing of
re-evaluation scans established and resources optimized.
These considerations will be even more important in the
future, as the indications for the use of immunotherapy are
expanding. Ipilimumab, for example, has been investigated in
a phase II trial in combination with chemotherapy (carboplatin
plus paclitaxel, CP) in patients with extensive disease small-
cell lung cancer (ED-SCLC) or stage IIIB/IV non-small-cell
lung cancer (NSCLC). Two dosing schedules were explored:
concurrently with CP or after two cycles of CP (phased). A
substantial improvement in immune-related progression-free
survival (irPFS) andmodifiedWorld Health Organization PFS
was found in patients with NSCLC who received the phased
ipilimumab regimen compared with those who received CP
alone. Even patients with ED-SCLC treated with the same
regimen had a significant improvement in irPFS [21, 22].
Finally, in the field of melanoma imaging, several specific
molecular targets have been evaluated, including the
melanocortin receptor, the sigma receptor and melanin [23]. In
particular benzamide analogues, that are melanin-targeting
agents, have been among the most promising of the newer
melanoma radiotracers for both SPECT and PET imaging and
therapeutic applications [24]. Different compounds, such as 18F-
6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide
(18F-MEL050), N-[2-(diethylamino)-ethyl]-4-18F-
fluorobenzamide (18F-FBZA), N-[2-(diethylamino)-ethyl]-
2 - 1 8 F - f l u o r o p r o p a n am i d e ( 1 8 F - F PDA ) , 1 8 F -
N-[2-(diethylamino)ethyl]-6-fluoropyridine-3-carboxamide
( 1 8 F - I C F 0 1 0 0 6 ) a n d 6 8 G a - l a b e l l e d N - ( 2 -
diethylaminoethyl)benzamide derivative (68Ga-SCN-NOTA-
BZA), have been tested in the preclinical setting and have shown
high specificity for melanotic tissue and favourable in vivo phar-
macokinetics, suggesting great potential for noninvasive clinical
evaluation of melanin-positive melanoma [25–29]. These tracers
could be useful for the evaluation of response to immunotherapy,
given their specificity for melanoma cells that would allow
differentiation between disease locations and immune reactions
enhanced by treatment. Their investigation in prospective clinical
trials is highly desirable, as has already done with scintigraphic
tracers such as 123I-N-(2-diethylaminoethyl)-2-iodobenzamide
(123I-BZA2) that has demonstrated high accuracy in the diagno-
sis of melanin-positive metastatic melanoma [30]. Benzamide
analogues labelled with positron-emitting isotopes will probably
be more accurate, due to the higher resolution of PET than
SPECT images, and could also be used to noninvasively evaluate
patients for selective radionuclide therapy, as is done for neuro-
endocrine tumours with PET using 68Ga-DOTA conjugates.
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